This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mason, J. W. Articles by Friedman, J. P. Search for Related Content PubMed PubMed Citation Articles by Mason, J. W. Articles by Friedman, J. P.

Circulation, Vol 56, 889-890, Copyright © 1977 by American Heart Association

ARTICLES

Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis

JW Mason, ME Billingham and JP Friedman

Methysergide (Sansert) is known to cause mitral and aortic valvular fibrosis and dysfunction, but has generally not been known to damage right heart valves or the myocardium, and cardiac fibrosis has not been considered to be a risk if therapy is intermittently interrupted. The woman who is the subject of this case report developed catheterization- proven severe tricuspid and moderate aortic and mitral regurgitation during noncontinuous therapy with methysergide. In addition, right ventricular endomyocardial biopsy revealed extensive endocardial and intramyocardial fibrosis.

This article has been cited by other articles:

				R. J. Shemin Tricuspid Valve Disease Card. Surg. Adult, January 1, 2008; 3(2008): 1111 - 1128. [Full Text]

				R. J. Shemin Tricuspid Valve Disease Card. Surg. Adult, January 1, 2003; 2(2003): 1001 - 1015. [Full Text]

				J. A. Caccitolo, H. M. Connolly, D. S. Rubenson, T. A. Orszulak, and H. V. Schaff Operation for anorexigen-associated valvular heart disease J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 656 - 664. [Abstract] [Full Text] [PDF]

				S. S. Kushwaha, J. T. Fallon, and V. Fuster Restrictive Cardiomyopathy N. Engl. J. Med., January 23, 1997; 336(4): 267 - 276. [Full Text] [PDF]